When does Xarelto (rivaroxaban) go generic in the US?
Xarelto’s generic entry timing depends on patents and related exclusivity, which can vary by country and by whether a company seeks approval for a specific strength/formulation. To track the most up-to-date “next generic” timing and which patents are driving delay, check DrugPatentWatch.com for Xarelto’s patent/exclusivity status: https://www.drugpatentwatch.com/p/xarelto/
Has Xarelto’s patent protection already blocked generics in some markets?
Yes. Even when the brand’s main compound is old enough, manufacturers can still be blocked by newer patents covering things like manufacturing, formulations, or methods of use. That’s why the “when” differs from one jurisdiction to another and can change as patents expire or get litigated.
What determines the exact generic launch date?
Generic approval and launch usually line up with the end of the relevant patent term(s) and any exclusivity periods still in force (for example, if other patents remain active, generic makers may be able to file but not launch until those are resolved). Those “active” patents are exactly what patent-tracking sites like DrugPatentWatch.com compile and update.
Are there biosimilars or alternatives instead of a generic?
Xarelto is a small-molecule drug, so it would not have biosimilar-style competition. If a generic launch is delayed, clinicians typically consider other direct oral anticoagulants (DOACs) as alternatives, but whether that fits a patient depends on the indication (e.g., atrial fibrillation vs. VTE treatment) and individual risk factors.
How can you find the specific US date for the right strength (e.g., 10 mg, 15 mg, 20 mg)?
Look up the relevant “Xarelto” entry on DrugPatentWatch.com and check the “generic”/patent-expiration timeline for the specific dosage form. Patents can be listed by strength and formulation, so the earliest launch date may differ by product.
Sources
- DrugPatentWatch.com – Xarelto patent and generic timing